These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35071987)

  • 1. Sub-acute Onset of Guillain-Barré Syndrome Post-mRNA-1273 Vaccination: a Case Report.
    Nagalli S; Shankar Kikkeri N
    SN Compr Clin Med; 2022; 4(1):41. PubMed ID: 35071987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.
    Meo SA; Shaikh N; Abukhalaf FA; Meo AS
    Sci Rep; 2024 Aug; 14(1):18767. PubMed ID: 39138276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
    Osowicki J; Morgan HJ; Harris A; Clothier HJ; Buttery JP; Kiers L; Crawford NW;
    Vaccine; 2022 Dec; 40(52):7579-7585. PubMed ID: 36357291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database.
    Kim JE; Park J; Min YG; Hong YH; Song TJ
    J Peripher Nerv Syst; 2022 Sep; 27(3):206-214. PubMed ID: 35751472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute-onset chronic inflammatory demyelinating polyneuropathy following AstraZeneca COVID-19 vaccine: a case report.
    Smaoui E; Moalla KS; Bouattour N; Farhat N; Sakka S; Daoud S; Damak M; Mhiri C
    Pan Afr Med J; 2024; 47():46. PubMed ID: 38681104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guillain-Barré syndrome after COVID-19 vaccines: A Tunisian case series.
    Berrim K; Lakhoua G; Zaiem A; Charfi O; Aouinti I; Kastalli S; Daghfous R; El Aidli S
    Br J Clin Pharmacol; 2023 Feb; 89(2):574-578. PubMed ID: 36398559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.
    García-Grimshaw M; Galnares-Olalde JA; Bello-Chavolla OY; Michel-Chávez A; Cadena-Fernández A; Briseño-Godínez ME; Antonio-Villa NE; Núñez I; Gutiérrez-Romero A; Hernández-Vanegas L; Del Mar Saniger-Alba M; Carrillo-Mezo R; Ceballos-Liceaga SE; Carbajal-Sandoval G; Flores-Silva FD; Díaz-Ortega JL; Cortes-Alcalá R; Pérez-Padilla JR; López-Gatell H; Chiquete E; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
    Eur J Neurol; 2022 Nov; 29(11):3368-3379. PubMed ID: 35841212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?
    Oo WM; Giri P; de Souza A
    J Neuroimmunol; 2021 Nov; 360():577719. PubMed ID: 34560365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guillain-Barré Syndrome After Ad26.COV2.S Vaccination.
    Thant HL; Morgan R; Paese MM; Persaud T; Diaz J; Hurtado L
    Am J Case Rep; 2022 Feb; 23():e935275. PubMed ID: 35157644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute-onset chronic inflammatory demyelinating polyneuropathy complicating SARS-CoV-2 infection and Ad26.COV2.S vaccination: report of two cases.
    Fotiadou A; Tsiptsios D; Karatzetzou S; Kitmeridou S; Iliopoulos I
    Egypt J Neurol Psychiatr Neurosurg; 2022; 58(1):116. PubMed ID: 36212671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute-onset chronic inflammatory demyelinating polyneuropathy after COVID-19 infection and subsequent ChAdOx1 nCoV-19 vaccination.
    Suri V; Pandey S; Singh J; Jena A
    BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34607818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guillain-Barré syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases.
    Bouattour N; Hdiji O; Sakka S; Fakhfakh E; Moalla K; Daoud S; Farhat N; Damak M; Mhiri C
    Neurol Sci; 2022 Feb; 43(2):755-761. PubMed ID: 34796417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post coronavirus disease-2019 vaccination Guillain-Barré syndrome.
    Biswas A; Pandey SK; Kumar D; Vardhan H
    Indian J Public Health; 2021; 65(4):422-424. PubMed ID: 34975092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine.
    Nasuelli NA; De Marchi F; Cecchin M; De Paoli I; Onorato S; Pettinaroli R; Savoini G; Godi L
    Neurol Sci; 2021 Nov; 42(11):4747-4749. PubMed ID: 34272622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
    Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
    JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccine-related Guillain-Barré syndrome in the Liguria region of Italy: A multicenter case series.
    Germano F; Bellucci M; Grisanti S; Beronio A; Grazzini M; Coco E; Tassinari T; Della Cava F; De Michelis C; Baldi O; Sivori G; Murialdo A; Cabona C; Durando P; Uccelli A; Schenone A; Franciotta D; Benedetti L
    J Neurol Sci; 2022 Sep; 440():120330. PubMed ID: 35802961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
    Introna A; Caputo F; Santoro C; Guerra T; Ucci M; Mezzapesa DM; Trojano M
    Clin Neurol Neurosurg; 2021 Sep; 208():106887. PubMed ID: 34418708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two possible etiologies of Guillain-Barré syndrome: mRNA-1273 (Moderna) vaccination and scrub typhus: A case report.
    Hwang BW; Bong JB
    Medicine (Baltimore); 2022 Dec; 101(48):e32140. PubMed ID: 36482517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 Vaccination a Cause of Guillain-Barré Syndrome? A Case Series.
    Nagdev G; Chavan G; Sahu G; Devasilpa Raju PD
    Cureus; 2022 Oct; 14(10):e30888. PubMed ID: 36465787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.